Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06005441 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.
A Phase 2 study, sponsored by Caliway Biopharmaceuticals Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT06005441 is a Phase 2 study that has completed, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 173 participants.
The verdict
NCT06005441, a Phase 2 study, has completed, sponsored by Caliway Biopharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared with CBL-A1 and CBL-A2 for reducing subcutaneous fat.
Interventions
- DRUG CBL-514 injection
- DRUG 0.9% Sodium Chloride
- DRUG CBL-A1 Injection
- DRUG CBL-A2 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2024-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06005441
The ClinicalTrials.gov registry entry for NCT06005441 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caliway Biopharmaceuticals Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CBL-514 injection is the first listed.
NCT06005441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06005441 about?
NCT06005441 is a clinical study titled "A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.". This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared with CBL-A1 and CBL-A2 for reducing subcutaneous fat.
What is the current status of trial NCT06005441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2023-11-10. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT06005441?
The interventions under investigation include: CBL-514 injection (DRUG), 0.9% Sodium Chloride (DRUG), CBL-A1 Injection (DRUG), CBL-A2 Injection (DRUG).
Who is sponsoring clinical trial NCT06005441?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.